Article information
Las clasificaciones actuales de la hipertensión pulmonar han contribuido significativamente al conocimiento de la enfermedad vascular pulmonar, han facilitado ensayos farmacológicos y han mejorado nuestro conocimiento de las cardiopatías congénitas del adulto; sin embargo estas clasificaciones no son aplicables completamente a la enfermedad en el niño. La clasificación que aquí se propone se basa principalmente en la práctica clínica. Los objetivos específicos de esta nueva clasificación son mejorar las estrategias diagnósticas, promover la investigación clínica, mejorar nuestro conocimiento de la patogénesis, de la fisiología y de la epidemiología de la enfermedad y orientar el desarrollo de modelos de la enfermedad humana en el laboratorio y estudios en animales; también puede servir como un recurso docente. Se hace énfasis en los conceptos de maladaptación perinatal, alteraciones del desarrollo e hipoplasia pulmonar como factores causantes de la hipertensión pulmonar pediátrica; así mismo, en la importancia de los múltiples síndromes malformativos congénitos, genéticos y cromosómicos en la presentación de la hipertensión pulmonar pediátrica. La enfermedad vascular pulmonar hipertensiva en niños se divide en diez grandes categorías.
Palabras clave:
hipertensión arterial pulmonar
cardiopatía congénita
Pediatría
Current classifications of pulmonary hypertension have contributed a great deal to our understanding of pulmonary vascular disease, facilitated drug trials, and improved our understanding of congenital heart disease in adult survivors. However, these classifications are not applicable readily to pediatric disease. The classification system that we propose is based firmly in clinical practice. The specific aims of this new system are to improve diagnostic strategies, to promote appropriate clinical investigation, to improve our understanding of disease pathogenesis, physiology and epidemiology, and to guide the development of human disease models in laboratory and animal studies. It should be also an educational resource. We emphasize the concepts of perinatal maladaptation, maldevelopment and pulmonary hypoplasia as causative factors in pediatric pulmonary hypertension. We highlight the importance of genetic, chromosomal and multiple congenital malformation syndromes in the presentation of pediatric pulmonary hypertension. We divide pediatric pulmonary hypertensive vascular disease into 10 broad categories.
Keywords:
pulmonary arterial hypertension
congenital heart disease
Pediatrics
Full text is only aviable in PDF
Bibliografía
[1.]
Rich S. Primary pulmonary hypertension: Executive summary from the world symposium-primary pulmonary hypertension 1998. Paper presented at: World Health Organisation, 1998; Evian.
[2.]
G. Simonneau, N. Galie, L.J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, et al.
Clinical classification of pulmonary hypertension.
J Am Coll Cardiol, 43 (2004), pp. 5S-12S
[3.]
G. Simonneau, I.M. Robbins, M. Beghetti, R.N. Channick, M. Delcroix, C.P. Denton, et al.
Updated clinical classification of pulmonary hypertension.
J Am Coll Cardiol, 54 (2009), pp. S43-S54
[4.]
G. Díaz.
Aspectos generales; definición clasificación y epidemiología.
Hipertensión Pulmonar en Niños, pp. 9-19
[5.]
M.E. van Albada, R.M. Berger.
Pulmonary arterial hypertension in congenital cardiac disease -the need for refinement of the Evian-Venice classification.
Cardiol Young, 18 (2008), pp. 10-17
[6.]
R.L. van Loon, M.T. Roofthooft, M. van Osch-Gevers, T. Delhaas, J.L. Strengers, N.A. Blom, et al.
Clinical characterization of pediatric pulmonary hypertension: Complex presentation and diagnosis.
J Pediatr, 155 (2009), pp. 176-1820
[7.]
I. Schulze-Neick, M. Beghetti.
Classifying pulmonary hypertension in the setting of the congenitally malformed heart—cleaning up a dog's dinner.
Cardiol Young, 18 (2008), pp. 22-25
[8.]
D.J. Barker.
The developmental origins of adult disease.
J Am Coll Nutr, 23 (2004), pp. 588S-S595
[10.]
S.H. Abman.
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease.
Adv Exp Med Biol, 661 (2010), pp. 323-335
[11.]
P. Eulmesekian, E. Cutz, B. Parvez, D. Bohn, I. Adatia.
Alveolar capillary dysplasia: A six-year single center experience.
J Perinat Med, 33 (2005), pp. 347-352
[12.]
R. Rowe, L. James.
The normal pulmonary arterial pressure during the first year of life.
J Pediatr, 51 (1957), pp. 1-4
[13.]
J. Lock, S. Einzig, J. Moller.
Hemodynamic responses to exercise in normal children.
Am J Cardiol, 41 (1978), pp. 1278-1284
[15.]
A.R. Hansen, C.M. Barnes, J. Folkman, T.F. McElrath.
Maternal preeclampsia predicts the development of bronchopulmonary dysplasia.
J Pediatr, 156 (2010), pp. 532-536
[16.]
Y.V. Maeno, S.A. Kamenir, B. Sinclair, M.E. van der Velde, J.F. Smallhorn, L.K. Hornberger.
Prenatal features of ductus arteriosus constriction and restrictive foramen ovale in d-transposition of the great arteries.
Circulation, 99 (1999), pp. 1209-1214
[17.]
M. Castillo, A. Vade, J.E. Lim-Dunham, E. Masuda, R. Massarani-Wafai.
Pulmonary interstitial glycogenosis in the setting of lung growth abnormality: Radiographic and pathologic correlation.
Pediatr Radiol, 40 (2010), pp. 1562-1565
[18.]
G.H. Deutsch, L.R. Young, R.R. Deterding, L.L. Fan, S.D. Dell, J.A. Bean, et al.
Diffuse lung disease in young children: Application of a novel classification scheme.
Am J Respir Crit Care Med, 176 (2007), pp. 1120-1128
[19.]
S. Chen, P.C. Ursell, I. Adatia, A.A. Hislop, P. Giannikopoulos, L.K. Hornberger.
Prenatal diagnosis of primary pulmonary hypoplasia in fraternal twins.
Ultrasound Obstet Gynecol, 35 (2010), pp. 113-116
[20.]
D. Inwald, K. Brown, F. Gensini, M. Malone, A. Goldman.
Open lung biopsy in neonatal and paediatric patients referred for extracorporeal membrane oxygenation (ECMO).
Thorax, 59 (2004), pp. 328-333
[21.]
S. Yu, L. Shao, H. Kilbride, D.L. Zwick.
Haploinsufficiencies of FOXF1 and FOXC2 genes associated with lethal alveolar capillary dysplasia and congenital heart disease.
Am J Med Genet A, 152 (2010), pp. 1257-1262
[22.]
P. Stankiewicz, P. Sen, S.S. Bhatt, M. Storer, Z. Xia, B.A. Bejjani, et al.
Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations.
Am J Hum Genet, 84 (2009), pp. 780-791
[23.]
C. Shaw-Smith.
Genetic factors in esophageal atresia, tracheo-esophageal fistula and the VACTERL association: Roles for FOXF1 and the 16q24.1 FOX transcription factor gene cluster, and review of the literature.
Eur J Med Genet, 53 (2010), pp. 6-13
[24.]
H.B. Vassal, M. Malone, A.J. Petros, R.M. Winter.
Familial persistent pulmonary hypertension of the newborn resulting from misalignment of the pulmonary vessels (congenital alveolar capillary dysplasia).
J Med Genet, 35 (1998), pp. 58-60
[25.]
R.N. Han, S. Babaei, M. Robb, T. Lee, R. Ridsdale, C. Ackerley, et al.
Defective lung vascular development and fatal respiratory distress in endothelial NO synthasedeficient mice: A model of alveolar capillary dysplasia?.
Circ Res, 94 (2004), pp. 1115-1123
[26.]
M. Kitagawa, A. Hislop, E.A. Boyden, L. Reid.
Lung hypoplasia in congenital diaphragmatic hernia: A quantitative study of airway, artery, and alveolar development.
Br J Surg, 58 (1971), pp. 342-346
[27.]
T.P. Cooney, W.M. Thurlbeck.
Pulmonary hypoplasia in Down's syndrome.
N Engl J Med, 307 (1982), pp. 1170-1173
[28.]
D.M. Sherer, J.M. Davis, J.R. Woods.
Jr Pulmonary hypoplasia: A review.
Obstet Gynecol Surv, 45 (1990), pp. 792-803
[29.]
S.S. Askenazi, M. Perlman.
Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis.
Arch Dis Child, 54 (1979), pp. 614-618
[30.]
J.D. Murphy, G.F. Vawter, L.M. Reid.
Pulmonary vascular disease in fatal meconium aspiration.
J Pediatr, 104 (1984), pp. 758-762
[31.]
R.L. Geggel, L.M. Reid.
The structural basis of PPHN.
Clin Perinatol, 11 (1984), pp. 525-549
[32.]
S.G. Haworth, L. Reid.
Persistent fetal circulation: Newly recognized structural features.
J Pediatr, 88 (1976), pp. 614-620
[33.]
L. Guillot, A. Carre, G. Szinnai, M. Castanet, E. Tron, F. Jaubert, et al.
NKX2 1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “Brain-Lung-Thyroid Syndrome”.
Hum Mutat, 31 (2010), pp. E1146-E1162
[34.]
V. Boggaram.
Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung.
Clin Sci (Lond), 116 (2009), pp. 27-35
[35.]
J.P. Kinsella, S.R. Neish, E. Shaffer, S.H. Abman.
Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn.
Lancet, 340 (1992), pp. 819-820
[36.]
J.P. Kinsella, S.H. Abman.
Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn.
J Pediatr, 126 (1995), pp. 853-864
[37.]
S.H. Abman, B.A. Chatfield, S.L. Hall, I.F. McMurtry.
Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth.
Am J Physiol, 259 (1990), pp. H1921-H1927
[38.]
R.H. Steinhorn, J.P. Kinsella, C. Pierce, G. Butrous, M. Dilleen, M. Oakes, et al.
Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension.
J Pediatr, 155 (2009), pp. 841-847
[39.]
R.H. Steinhorn.
Neonatal pulmonary hypertension.
Pediatr Crit Care Med, 11 (2010), pp. S79-S84
[40.]
B. Thebaud, D. Tibboel.
Pulmonary hypertension associated with congenital diaphragmatic hernia.
Cardiol Young, 19 (2009), pp. 49-53
[41.]
J.P. Kinsella, D.D. Ivy, S.H. Abman.
Pulmonary vasodilator therapy in congenital diaphragmatic hernia: Acute, late, and chronic pulmonary hypertension.
Semin Perinatol, 29 (2005), pp. 123-128
[42.]
A.C. Chang, D. Macrae.
Neonates with congenital cardiac defects and pulmonary hypertension.
Cardiol Young, 19 (2009), pp. 4-7
[43.]
H. Baquero, A. Soliz, F. Neira, M.E. Venegas, A. Sola.
Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study.
Pediatrics, 117 (2006), pp. 1077-1083
[44.]
D. Peñaloza, F. Sime, L. Ruiz.
Pulmonary hemodynamics in children living at high altitudes.
High Alt Med Biol, 9 (2008), pp. 199-207
[45.]
G. Díaz, A. Márquez.
Hipertensión pulmonar en niños a moderada altura. En: hipertensión pulmonar en niños.
Hipertensión Pulmonar en Niños, pp. 266-284
[46.]
R. Gamboa, E. Marticorena.
Pulmonary arterial pressure in newborn infants in high altitude.
Arch Inst Biol Andina, 4 (1971), pp. 55-66
[47.]
S.G. Haworth, A.A. Hislop.
Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006.
Heart, 95 (2009), pp. 312-317
[48.]
I. Adatia, S.S. Kothari, J.A. Feinstein.
Pulmonary hypertension associated with congenital heart disease: Pulmonary vascular disease: The global perspective.
Chest, 137 (2010), pp. 52S-61S
[49.]
M.S. Fasnacht, J.F. Tolsa, M. Beghetti.
The Swiss registry for pulmonary arterial hypertension: The paediatric experience.
Swiss Med Wkly, 137 (2007), pp. 510-513
[50.]
I. Adatia, M. Mullen, T.J. Kulik.
Pulmonary venous hypertension or pulmonary hypertension due to left heart disease.
Prog Pediatr Cardiol, 27 (2009), pp. 35-42
[51.]
T. Kulik, M. Mullen, I. Adatia.
Pulmonary arterial hypertension associated with congenital heart disease.
Prog Pediatr Cardiol, 27 (2009), pp. 25-33
[52.]
K.E. Roberts, J.J. McElroy, W.P. Wong, E. Yen, A. Widlitz, R.J. Barst, et al.
BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.
Eur Respir J, 24 (2004), pp. 371-374
[53.]
R. Cordina, D. Celermajer.
Late-onset pulmonary arterial hypertension after a successful atrial or arterial switch procedure for transposition of the great arteries.
Pediatr Cardiol, 31 (2010), pp. 238-241
[54.]
A. Kumar, G. Taylor, G. Sandor, M. Patterson.
Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum.
Br Heart J, 69 (1993), pp. 442-445
[55.]
N. Sreeram, A. Petros, I. Peart, R. Arnold.
Progressive pulmonary hypertension after the arterial switch procedure.
Am J Cardiol, 73 (1994), pp. 620-621
[56.]
L. Daliento, J. Somerville, P. Presbitero, L. Menti, S. Brach-Prevert, G. Rizzoli, et al.
Eisenmenger syndrome factors relating to deterioration and death.
Eur Heart J, 19 (1998), pp. 1845-1855
[57.]
R.L. van Loon, E.S. Hoendermis, M.G. Duffels, A. Vonk-Noordegraaf, B.J. Mulder, H.L. Hillege, et al.
Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist?.
Am Heart J, 154 (2007), pp. 776-782
[58.]
A.J. Bograd, S. Mital, J.C. Schwarzenberger, R.S. Mosca, J.M. Quaegebeur, L.J. Addonizio, et al.
Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006.
Am J Transplant, 8 (2008), pp. 201-207
[59.]
B. Daftari, J.C. Alejos, G. Perens.
Initial experience with sildenafil, bosentan, and nitric oxide for pediatric cardiomyopathy patients with elevated pulmonary vascular resistance before and after orthotopic heart transplantation.
J Transplant, 2010 (2010), pp. 656984
[60.]
M.R. de Leval.
The Fontan circulation: A challenge to William Harvey?.
Nat Clin Pract Cardiovasc Med, 2 (2005), pp. 202-208
[61.]
M.R. de Leval, J.E. Deanfield.
Four decades of Fontan palliation.
Nat Rev Cardiol, 7 (2010), pp. 520-527
[62.]
S. Khambadkone, J. Li, M.R. de Leval, S. Cullen, J.E. Deanfield, A.N. Redington.
Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation.
Circulation, 107 (2003), pp. 3204-3208
[63.]
A. La Gerche, M. Gewillig.
What limits cardiac performance during exercise in normal subjects and in healthy Fontan patients?.
Int J Pediatr, (2010),
[64.]
A. Giardini, A. Balducci, S. Specchia, G. Gargiulo, M. Bonvicini, F.M. Picchio.
Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients.
Eur Heart J, 29 (2008), pp. 1681-1687
[65.]
T. Humpl, J.T. Reyes, H. Holtby, D. Stephens, I. Adatia.
Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study.
Circulation, 111 (2005), pp. 3274-3280
[66.]
S.C. Apostolopoulou, J. Papagiannis, S. Rammos.
Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.
J Heart Lung Transplant, 24 (2005), pp. 1174-1176
[67.]
O. Uzun, J.K. Wong, V. Bhole, O. Stumper.
Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan.
Ann Thorac Surg, 82 (2006), pp. e39-e40
[68.]
C. Ovaert, D. Thijs, D. Dewolf, J. Ottenkamp, H. Dessy, P. Moons, et al.
The effect of bosentan in patients with a failing Fontan circulation.
Cardiol Young, 19 (2009), pp. 331-339
[69.]
A. Heath, K. Stewart, J. Mendes, M. Ramirez, F. Freudenthal.
Does High altitude protect against irreversible pulmonary hypertension?.
PVRI Rev, 2 (2010), pp. 131-133
[70.]
F. Sime, N. Banchero, D. Peñaloza, R. Gamboa, J. Cruz, E. Marticorena.
Pulmonary hypertension in children born and living at high altitudes.
Am J Cardiol, 11 (1963), pp. 143-149
[71.]
D. Penaloza, J. Arias-Stella, F. Sime, S. Recavarren, E. Marticorena.
The Heart and pulmonary circulation in children at high altitudes: physiological, anatomical, and clinical observations.
Pediatrics, 34 (1964), pp. 568-582
[72.]
D. Penaloza, J. Arias-Stella.
The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness.
Circulation, 115 (2007), pp. 1132-1146
[73.]
E. Cutz, D. Chiasson.
Chronic lung disease after premature birth.
N Engl J Med, 358 (2008), pp. 743-745
[74.]
P.M. Mourani, M. Mullen, S.H. Abman.
Pulmonary hypertension in bronchopulmonary dysplasia.
Prog Pediatr Cardiol, 27 (2009), pp. 43-48
[75.]
K.R. Stenmark, S.H. Abman.
Lung vascular development: Implications for the pathogenesis of bronchopulmonary dysplasia.
Annu Rev Physiol, 67 (2005), pp. 623-661
[76.]
J.J. Coalson.
Pathology of new bronchopulmonary dysplasia.
Semin Neonatol, 8 (2003), pp. 73-81
[77.]
E. Bancalari, N. Claure.
Definitions and diagnostic criteria for bronchopulmonary dysplasia.
Semin Perinatol, 30 (2006), pp. 164-170
[78.]
E. Baraldi, M. Filippone.
Chronic lung disease after premature birth.
N Engl J Med, 357 (2007), pp. 1946-1955
[79.]
E. Khemani, D.B. McElhinney, L. Rhein, O. Andrade, R.V. Lacro, K.C. Thomas, et al.
Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: Clinical features and outcomes in the surfactant era.
Pediatrics, 120 (2007), pp. 1260-1269
[80.]
U. Krishnan, S. Krishnan, M. Gewitz.
Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies.
Pediatr Cardiol, 29 (2008), pp. 1082-1086
[81.]
D.M. Drossner, D.W. Kim, K.O. Maher, W.T. Mahle.
Pulmonary vein stenosis: Prematurity and associated conditions.
Pediatrics, 122 (2008), pp. e656-e661
[82.]
A.N. Seale, S.A. Webber, H. Uemura, J. Partridge, M. Roughton, S.Y. Ho, et al.
Pulmonary vein stenosis: The UK, Ireland and Sweden collaborative study.
Heart, 95 (2009), pp. 1944-1949
[83.]
P.M. Mourani, M.K. Sontag, D.D. Ivy, S.H. Abman.
Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease.
J Pediatr, 154 (2009), pp. 379-384
[84.]
S. Moledina, A.A. Hislop, H. Foster, I. Schulze-Neick, S.G. Haworth.
Childhood idiopathic pulmonary arterial hypertension: A national cohort study.
Heart, 96 (2010), pp. 1401-1406
[85.]
B. Girerd, D. Montani, F. Coulet, B. Sztrymf, A. Yaici, X. Jais, et al.
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.
Am J Respir Crit Care Med, 181 (2010), pp. 851-861
[86.]
A. Fraisse, X. Jais, J.M. Schleich, S. di Filippo, P. Maragnes, M. Beghetti, et al.
Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France.
Arch Cardiovasc Dis, 1 (2010), pp. 66-74
[87.]
R. Mathew, J. Huang, U.S. Katta, U. Krishnan, C. Sandoval, M.H. Gewitz.
Immunosuppressant- induced endothelial damage and pulmonary arterial hypertension.
J Pediatr Hematol Oncol, 33 (2011), pp. 55-58
[88.]
D. Yildizdas, S. Erdem, O. Kucukosmanoglu, M. Yilmaz, B. Yuksel.
Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Adv Ther, 25 (2008), pp. 515-519
[89.]
P. Silvani, A. Camporesi, A. Mandelli, A. Wolfler, I. Salvo.
A case of severe diazoxide toxicity.
Paediatr Anaesth, 14 (2004), pp. 607-609
[90.]
M.G. Karaman, F. Atalay, A.E. Tufan, A. Erdogan.
Pulmonary arterial hypertension in an adolescent treated with methylphenidate.
J Child Adolesc Psychopharmacol, 20 (2010), pp. 229-231
[91.]
L.V. Lewman.
Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets.
Hum Pathol, 3 (1972), pp. 67-70
[92.]
R.J. Barst, L. Abenhaim.
Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure.
Heart, 90 (2004), pp. e42
[93.]
M.S. Patel, G.P. Taylor, S. Bharya, N. Al-Sanna’a, I. Adatia, D. Chitayat, et al.
Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome.
Am J Med Genet, 129A (2004), pp. 294-299
[94.]
J.E. Bergman, K.D. Blake, M.K. Bakker, G.J. du Marchie Sarvaas, R.H. Free, C.M. van Ravenswaaij-Arts.
Death in CHARGE syndrome after the neonatal period.
Clin Genet, 77 (2010), pp. 232-240
[95.]
S. Baskar, M.L. Kulkarni, A.M. Kulkarni, S. Vittalrao, P.M. Kulkarni.
Adams-Oliver syndrome: Additions to the clinical features and possible role of BMP pathway.
Am J Med Genet A, 149 (2009), pp. 1678-1684
[96.]
O.M. Hess, J. Steurer, N.H. Goebel, U. Kuhlmann, H.P. Krayenbuhl.
Goldenhar syndrome.
Schweiz Med Wochenschr, 109 (1979), pp. 19-23
[97.]
I.R. Argueta-Morales, L.C. Meador, D.G. Nykanen, W.M. DeCampli.
Infantile form of scimitar syndrome with contralateral pulmonary vein stenosis.
Pediatr Cardiol, 31 (2010), pp. 550-552
[98.]
T. Salerno, P. Guccione, S. Malena, R. Cutrera.
Horseshoe lung associated with unique left pulmonary vein: An unreported association.
Pediatr Cardiol, 31 (2010), pp. 905-907
[99.]
C.L. Cua, A. Blankenship, A.L. North, J. Hayes, L.D. Nelin.
Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates.
Pediatr Cardiol, 28 (2007), pp. 250-254
[100.]
O.R. Levine, R.C. Harris, W.A. Blanc, R.B. Mellins.
Progressive pulmonary hypertension in children with portal hypertension.
J Pediatr, 83 (1973), pp. 964-972
[101.]
S. Simeoni, A. Puccetti, M. Chilosi, E. Tinazzi, D. Prati, R. Corrocher, et al.
Type 1 neurofibromatosis complicated by pulmonary artery hypertension: A case report.
J Med Invest, 54 (2007), pp. 354-358
[102.]
D.R. Stewart, J.D. Cogan, M.R. Kramer, W.T. Miller Jr., L.E. Christiansen, M.W. Pauciulo, et al.
Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?.
Chest, 132 (2007), pp. 798-808
[103.]
P.J. Engel, R.P. Baughman, S.G. Menon, D.J. Kereiakes, L. Taylor, M. Scott.
Pulmonary hypertension in neurofibromatosis.
Am J Cardiol, 99 (2007), pp. 1177-1178
[104.]
Y. Aoki, M. Kodama, T. Mezaki, R. Ogawa, M. Sato, M. Okabe, et al.
von Recklinghausen disease complicated by pulmonary hypertension.
Chest, 119 (2001), pp. 1606-1608
[105.]
S. Banka, W.G. Newman, R.K. Ozgul, A. Dursun.
Mutations in the G6PC3 gene cause Dursun syndrome.
Am J Med Genet A, 152 (2010), pp. 2609-2611
[106.]
I. Scurr, L. Wilson, M. Lees, S. Robertson, E. Kirk, A. Turner, et al.
Cantu syndrome: Report of nine new cases and expansion of the clinical phenotype.
Am J Med Genet A, 155 (2011), pp. 508-518
[107.]
K. Suzuki, S. Yamaki, S. Mimori, Y. Murakami, K. Mori, Y. Takahashi, et al.
Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect.
Am J Cardiol, 86 (2000), pp. 434-437
[108.]
Y. Matsumura, N. Ban, N. Inagaki.
Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease.
Am J Physiol Lung Cell Mol Physiol, 295 (2008), pp. L698-L707
[109.]
S.K. Park, L. Amos, A. Rao, M.W. Quasney, Y. Matsumura, N. Inagaki, et al.
Identification and characterization of a novel ABCA3 mutation.
Physiol Genomics, 40 (2010), pp. 94-99
[110.]
P.S. Babyn, H.K. Gahunia, P. Massicotte.
Pulmonary thromboembolism in children.
Pediatr Radiol, 35 (2005), pp. 258-274
[111.]
B. Tavil, B. Kuskonmaz, N. Kiper, M. Cetin, F. Gumruk, A. Gurgey.
Pulmonary thromboembolism in childhood: A single-center experience from Turkey.
Heart Lung, 38 (2009), pp. 56-65
[112.]
Y. Brandstetter, E. Weinhouse, M.L. Splaingard, T.T. Tang.
Cor pulmonale as a complication of methylmalonic acidemia and homocystinuria (Cbl-C type) Am J Med Genet, 36 (1990), pp. 167-171
[113.]
J.A. Staser, T. Alam, K. Applegate.
Calcified pulmonary thromboembolism in a child with sickle cell disease: Value of multidetector CT in patients with acute chest syndrome.
Pediatr Radiol, 36 (2006), pp. 561-563
[114.]
D. Bonderman, H. Wilkens, S. Wakounig, H.J. Schafers, P. Jansa, J. Lindner, et al.
Risk factors for chronic thromboembolic pulmonary hypertension.
Eur Respir J, 33 (2009), pp. 325-331
[115.]
G.L. Branch, R.F. Castle.
Thromboembolic complications in primary endocardial fibroelastosis.
J Pediatr, 69 (1966), pp. 250-258
[116.]
J.N. Johnson, D.J. Driscoll, C.G. McGregor.
Pulmonary thromboendarterectomy in adolescents and young adults.
Pediatr Pulmonol, 45 (2010), pp. 614-618
[117.]
V. Lambert, P. Durand, D. Devictor, C. Planche, A. Serraf.
Unilateral right pulmonary thromboendarterectomy for chronic embolism: A successful procedure in an infant.
J Thorac Cardiovasc Surg, 118 (1999), pp. 953-954
[118.]
B.M. Groves, T. Droma, J.R. Sutton, R.G. McCullough, R.E. McCullough, J. Zhuang, et al.
Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m.
J Appl Physiol, 74 (1993), pp. 312-318
[119.]
K.A. Fagan, J.V. Weil.
Potential genetic contributions to control of the pulmonary circulation and ventilation at high altitude.
High Alt Med Biol, 2 (2001), pp. 165-171
[120.]
M. Yaron, S. Niermeyer, K.N. Lindgren, B. Honigman, J.D. Strain, C.B. Cairns.
Physiologic response to moderate altitude exposure among infants and young children.
High Alt Med Biol, 4 (2003), pp. 53-59
[121.]
M. Maggiorini, F. Leon-Velarde.
High-altitude pulmonary hypertension: A pathophysiological entity to different diseases.
Eur Respir J, 22 (2003), pp. 1019-1025
[122.]
J.W. Fasules, J.W. Wiggins, R.R. Wolfe.
Increased lung vasoreactivity in children from Leadville.
Colorado, after recovery from high-altitude pulmonary edema. Circulation, 72 (1985), pp. 957-962
[123.]
A.L. Gabry, X. Ledoux, M. Mozziconacci, C. Martin.
High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): A series of 52 patients.
Chest, 123 (2003), pp. 49-53
[124.]
B.B. Das, R.R. Wolfe, K.C. Chan, G.L. Larsen, J.T. Reeves, D. Ivy.
High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude.
Arch Pediatr Adolesc Med, 158 (2004), pp. 1170-1176
[125.]
A.G. Durmowicz.
Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes.
Pediatrics, 108 (2001), pp. 443-447
[126.]
G.J. Sui, Y.H. Liu, X.S. Cheng, I.S. Anand, E. Harris, P. Harris, et al.
Subacute infantile mountain sickness.
J Pathol, 155 (1988), pp. 161-170
[127.]
D.D. Ivy, J.A. Feinstein, T. Humpl, E.B. Rosenzweig.
Non-congenital heart disease associated pediatric pulmonary arterial hypertension.
Prog Pediatr Cardiol, 27 (2009), pp. 13-23
[128.]
S. Cataltepe, L.J. van Marter, H. Kozakewich, D.L. Wessel, P.J. Lee, H.L. Levy.
Pulmonary hypertension associated with nonketotic hyperglycinaemia.
J Inherit Metab Dis, 23 (2000), pp. 137-144
[129.]
M. del Toro, J.A. Arranz, A. Macaya, E. Riudor, M. Raspall, A. Moreno, et al.
Progressive vacuolating glycine leukoencephalopathy with pulmonary hypertension.
Ann Neurol, 60 (2006), pp. 148-152
[130.]
G.N. Leal, A.C. de Paula, C. Leone, C.A. Kim.
Echocardiographic study of paediatric patients with mucopolysaccharidosis.
Cardiol Young, 20 (2010), pp. 254-261
[131.]
M. Ueno, T. Murakami, A. Takeda, M. Kubota.
Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease.
Circ J, 73 (2009), pp. 1965-1968
[132.]
T. Hino, A. Hayashida, N. Okahashi, N. Wada, N. Watanabe, K. Obase, et al.
Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan.
Intern Med, 48 (2009), pp. 597-600
[133.]
T. Ohno, J. Muneuchi, K. Ihara, T. Yuge, Y. Kanaya, S. Yamaki, et al.
Pulmonary hypertension in patients with congenital portosystemic venous shunt: A previously unrecognized association.
Pediatrics, 121 (2008), pp. e892-e899
[134.]
C.W. Iqbal, M.J. Krowka, T.H. Pham, D.K. Freese, M. El Youssef, M.B. Ishitani.
Liver transplantation for pulmonary vascular complications of pediatric end-stage liver disease.
J Pediatr Surg, 43 (2008), pp. 1813-1820
[135.]
B. Newman, J.A. Feinstein, R.A. Cohen, B. Feingold, J. Kreutzer, H. Patel, et al.
Congenital extrahepatic portosystemic shunt associated with heterotaxy and polysplenia.
Pediatr Radiol, 40 (2010), pp. 1222-1230
[136.]
M.H. Alghamdi, M. Steinraths, C. Panagiotopoulos, J.E. Potts, G.G. Sandor.
Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient.
Pediatr Cardiol, 31 (2010), pp. 872-874
[137.]
Y. Xing, H.M. Song, X.Y. Wu, Y.Y. He, M. Wei.
Clinical analysis of pulmonary arterial hypertension secondary to connective tissue disease in children.
Zhonghua Er Ke Za Zhi, 46 (2008), pp. 822-826
[138.]
S.G. Haworth, A. Hislop, L. Reid.
Editorial: Progressive pulmonary hypertension in children with portal hypertension.
J Pediatr, 84 (1974), pp. 783-785
[139.]
M.M. Silver, D. Bohn, D.H. Shawn, B. Shuckett, G. Eich, M. Rabinovitch.
Association of pulmonary hypertension with congenital portal hypertension in a child.
J Pediatr, 120 (1992), pp. 321-329
[140.]
R.L. Naeye.
“Primary” pulmonary hypertension with coexisting portal hypertension.A retrospective study of six cases.
Circulation, 22 (1960), pp. 376-384
[141.]
J.B. Saunders, T.J. Constable, D. Heath, P. Smith, A. Paton.
Pulmonary hypertension complicating portal vein thrombosis.
Thorax, 34 (1979), pp. 281-283
[142.]
J.S. Bower, D.R. Dantzker, B. Naylor.
Idiopathic pulmonary hypertension associated with nodular pulmonary infiltrates and portal venous thrombosis.
Chest, 78 (1980), pp. 111-113
[143.]
M.D. Cohen, L.J. Rubin, W.E. Taylor, J.A. Cuthbert.
Primary pulmonary hypertension: An unusual case associated with extrahepatic portal hypertension.
Hepatology, 3 (1983), pp. 588-592
[144.]
B.S. Edwards, E.K. Weir, W.D. Edwards, J. Ludwig, R.K. Dykoski, J.E. Edwards.
Coexistent pulmonary and portal hypertension: morphologic and clinical features.
J Am Coll Cardiol, 10 (1987), pp. 1233-1238
[145.]
C. Yutani, M. Imakita, H. Ishibashi-Ueda, S. Okubo, M. Naito, T. Kunieda.
Nodular regenerative hyperplasia of the liver associated with primary pulmonary hypertension.
Hum Pathol, 19 (1988), pp. 726-731
[146.]
I.R. Wanless, S. Albrecht, J. Bilbao, J.V. Frei, E.J. Heathcote, E.A. Roberts, et al.
Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: A new syndrome.
Mod Pathol, 2 (1989), pp. 56-62
[147.]
S. Padeh, R.M. Laxer, M.M. Silver, E.B. Silverman.
Primary pulmonaryy hypertension in a patient with systemic-onset juvenile arthritis.
Arthritis Rheum, 34 (1991), pp. 1575-1579
[148.]
P. Connor, P. Veys, P. Amrolia, S. Haworth, M. Ashworth, S. Moledina.
Pulmonary hypertension in children with Evans syndrome.
Pediatr Hematol Oncol, 25 (2008), pp. 93-98
[149.]
H. Nagai, K. Yasuma, T. Katsuki, A. Shimakura, K. Usuda, Y. Nakamura, et al.
Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival.A case report.
Angiology, 48 (1997), pp. 183-187
[150.]
G. Espinosa, R. Cervera, J. Font, R.A. Asherson.
The lung in the antiphospholipid syndrome.
Ann Rheum Dis, 61 (2002), pp. 195-198
[151.]
S. Sharma, A.L. Kirpalani, A. Kulkarni.
Severe pulmonary hypertension in a young patient with end-stage renal disease on chronic hemodialysis.
Ann Pediatr Cardiol, 3 (2010), pp. 184-186
[152.]
M. Yigla, F. Nakhoul, A. Sabag, N. Tov, B. Gorevich, Z. Abassi, et al.
Pulmonary hypertension in patients with end-stage renal disease.
Chest, 123 (2003), pp. 1577-1582
[153.]
A. Unal, M. Sipahioglu, F. Oguz, M. Kaya, H. Kucuk, B. Tokgoz, et al.
Pulmonary hypertension in peritoneal dialysis patients: Prevalence and risk factors.
Perit Dial Int, 29 (2009), pp. 191-198
[154.]
M. Amin, A. Fawzy, M.A. Hamid, A. Elhendy.
Pulmonary hypertension in patients with chronic renal failure: Role of parathyroid hormone and pulmonary artery calcifications.
Chest, 124 (2003), pp. 2093-2097
[155.]
Y. Havlucu, S. Kursat, C. Ekmekci, P. Celik, S. Serter, O. Bayturan, et al.
Pulmonary hypertension in patients with chronic renal failure.
Respiration, 74 (2007), pp. 503-510
[156.]
I. Adatia.
Pulmonary veno-occlusive disease.
The natural and modified history of congenital heart disease, pp. 513
[157.]
D. Kobayashi, A. Cook, D. Williams.
Pulmonary hypertension secondary to partial pulmonary venous obstruction in a child with Cantú syndrome.
Pediatr Radiol, 45 (2010), pp. 727-729
[158.]
M. Gewillig, S.C. Brown, L. De Catte, A. Debeer, B. Eyskens, V. Cossey, et al.
Premature foetal closure of the arterial duct: Clinical presentations and outcome.
Eur Heart J, 30 (2009), pp. 1530-1536
[159.]
L.J. Van Marter, A. Leviton, E.N. Allred, M. Pagano, K.F. Sullivan, A. Cohen, et al.
Persistent pulmonary artery hypertension of the newborn and smoking and aspirin and nonsteroidal anti inflammatory drug consumption during pregnancy.
Pediatrics, 97 (1996), pp. 658-663
[160.]
K.L. Siu, W.H. Lee.
Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension.
J Paediatr Child Health, 40 (2004), pp. 152-153
[161.]
B. Schiessl, K.T. Schneider, A. Zimmerman, F. Kainer, K. Friese, R. Oberhoffer.
Prenatal constriction of the fetal ductus arteriosus-related to maternal pain medication?.
Z Geburtshilfe Neonatol, 209 (2005), pp. 65-68
[162.]
M.A. Alano, E. Ngougmna, E.M. Ostrea Jr., G.G. Konduri.
Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn.
Pediatrics, 107 (2001), pp. 519-523
[163.]
M. Zender, J. Klinge, C. Kruger, H. Singer, J. Scharf.
Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: A case report.
J Perinat Med, 26 (1998), pp. 231-234
[164.]
C. Mas, S. Menahem.
Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac.
Aust N Z J Obstet Gynaecol, 39 (1999), pp. 106-107
Copyright © 2012. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular